Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 75 PS Ratio is 2.10 as of Jul. 20, 2026, which is 12% below its 10-year median of 2.38. GuruFocus rates ROCO:4153 with a GF Score™ of 75/100 and a GF Value™ of NT$38.01 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 61.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Diva Laboratories's share price is NT$31.00.
Diva Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$14.74. Hence, Diva Laboratories's PS Ratio for today is 2.10.
Good Sign:
Diva Laboratories Ltd stock PS Ratio (=2.1) is close to 2-year low of 2.02.
The historical rank and industry rank for Diva Laboratories's PS Ratio or its related term are showing as below:
ROCO:4153'
s PS Ratio Range Over the Past 10 Years
Min: 1.39 Med: 2.38 Max: 4.36
Current: 2.1
During the past 13 years, Diva Laboratories's highest PS Ratio was 4.36. The lowest was 1.39. And the median was 2.38.
ROCO:4153's PS Ratio is ranked better than 61.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.72
vs ROCO:4153: 2.10
Diva Laboratories Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Diva Laboratories was 0.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -5.40% per year.
During the past 13 years, Diva Laboratories's highest 3-Year average Revenue per Share Growth Rate was 17.60% per year. The lowest was -29.40% per year. And the median was -2.20% per year.
Back to Basics: PS Ratio
Diva Laboratories (ROCO:4153) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Diva Laboratories PS Ratio Related Terms
Diva Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diva Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Diva Laboratories's Share Price of today is NT$31.00. Diva Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$14.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Diva Laboratories (ROCO:4153) has a PS Ratio of 2.10 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Diva Laboratories and its competitors. This is 12% below median its historical median of 2.38. Over the past decade, Diva Laboratories' PS Ratio has ranged from 1.39 to 4.36. According to the industry distribution chart, Diva Laboratories ranks #77 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 38.5%.
Is Diva Laboratories' PS Ratio too high?
Diva Laboratories' current PS Ratio of 2.10 is 12% below median its 10-year median of 2.38. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 4.36. The Medical Diagnostics & Research industry median PS Ratio is 2.72. Diva Laboratories' value of 2.10 is 22.8% below this industry median. Based on the distribution chart, Diva Laboratories ranks #77 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #77 out of 200 companies for PS Ratio. This puts Diva Laboratories in the upper half of its industry. The industry median PS Ratio is 2.72. Diva Laboratories' value of 2.10 is 22.8% below this benchmark. Historically, Diva Laboratories' own PS Ratio has ranged from 1.39 to 4.36 over the past decade. While the company's 10-year median is 2.38 vs. the industry median of 2.72, Diva Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.72, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current PS Ratio of 2.10 is 22.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current PS Ratio is 2.10, which is 12% below median its own 10-year median of 2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.01, compared to a current price of NT$31.00 — trading 18.4% below its estimated fair value. The current PS Ratio is 2.10, which is 12% below median its 10-year median of 2.38 and 22.8% below the Medical Diagnostics & Research industry median of 2.72. Diva Laboratories' overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current PS Ratio is 2.10 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.00 is trading 18.4% below its estimated GF Value™ of NT$38.01.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
PS Ratio: 2.10 (12% below median its 10-year median of 2.38)
GF Value™: NT$38.01 vs. price of NT$31.00 (18.4% below fair value)
Industry Position: 22.8% below the Medical Diagnostics & Research median (#77 of 200)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
75GF Score
Get the complete analysis for ROCO:4153
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
